



CHARLES UNIVERSITY  
First Faculty of Medicine  
Department BIOCEV

## Material Transfer Agreement

This Material Transfer Agreement (hereinafter referred to as the "MTA") is concluded by and between

Charles University, having an office and place of business at Ovocný trh 560/5, Prague 1, 116 36, Czech Republic, concerning the Part: **First Faculty of Medicine** (whose address is: Kateřinská 32, 121 08 Prague 2, Czech Republic).  
(hereinafter referred to as the "Provider")

and

The Weizmann Institute of Science, having an office and place of business at 234 Herzl St. Rehovot, Israel.  
(hereinafter referred to as the "Recipient")

### 1. Definitions

- 1.1 Upon request the *Provider* shall provide to the *Recipient* the material as described and quantified in Annex 1, hereinafter referred to as the "*Original Material*". Annex 1 constitutes an integral part of this *MTA*.
- 1.2 "*Recipient*" is the legal entity as identified in Annex 1.
- 1.3 "*Recipient Scientist*" is the scientific employee of *Recipient* performing the intended experiments with *Material* as identified in Annex 1.
- 1.4 "*Progeny*" is defined as unmodified descendant from the *Original Material*, such as virus from virus, cell from cell, or organism from organism.
- 1.5 "*Unmodified Derivatives*" are substances created by the *Recipient* which constitute an unmodified functional subunit or product expressed by the *Original Material*, e.g. subclones of unmodified cell lines, purified or fractionated subsets of the *Original Material*, proteins expressed by DNA/RNA, or monoclonal antibodies secreted by a hybridoma cell line.
- 1.6 "*Modifications*" are substances created by the *Recipient* which contain/incorporate the *Original Material*, e.g. crosses, breeding varieties, cell fusions, subcloning, etc.
- 1.7 The "*Material*" which, regarding the inherent intellectual property rights, is and remains the exclusive property of the *Provider*, comprises particularly the *Original Material*, any *Progeny*, *Unmodified Derivatives*, the *Original Material* contained in *Modifications* and proprietary information concerning the *Original Material*.

### 2. Use of the *Material*

- 2.1 The *Recipient* shall use the *Material* in compliance with all laws and regulations applicable to such *Material* in the *Recipient's* place and country, including guidelines for work with recombinant DNA. The *Material* being experimental in nature must not be used in humans or animals unless - where applicable - explicitly admitted by an ethics committee or regulations on the treatment of laboratory animals.



Website:  
biocev.lf1.cuni.cz

E-mail:



Phone:



2.2 The *Material* shall be used exclusively for the purposes described in Annex 1. It must not be released to any person other than the *Recipient Scientist/s* named above and staff under their direct supervision, who are bound by obligations not less strict than those set out in this MTA. It shall be handled confidentially and forwarded to third parties only to the extent of *Provider's* prior written approval.

2.3 Upon request, the *Recipient* shall inform the *Provider* on the status of its research.

### 3. Publications

The *Recipient* shall have the right to publish its findings and results related to the *Material*, provided that the relevant *Provider Researcher/s* are either named as co-authors of the publication or cited as the source of the *Material*, according to the respective contribution of the *Material* to the publication. The *Recipient* shall submit all publications four weeks prior to their public disclosure to the *Provider*. The *Provider* agrees to keep *Recipient's* publication confidential until published by the *Recipient*.

### 4. Intellectual Property

4.1 Where the research involving the *Material* or a *Modification* results in an invention or a legally protectable *Modification* of the *Material*, the *Recipient* and *Recipient Scientist* shall promptly disclose this development to the *Provider*. *Recipient* and *Provider* shall decide in common about the inventorship, taking in due consideration the *Provider's* contribution to the invention through its *Material*. Decisions about all further proceedings, such as filing of a patent application or exploitation, shall be made after inventorship is determined.

4.2 At *Provider's* request, the *Recipient* agrees to provide the *Provider* for its internal research use with reasonable quantities of published materials developed, made or discovered in the course of *Recipient's* research studies using the *Material*, always provided that the *Recipient* may fulfill this obligation with reasonable effort. Such transfer shall be free of charge, but an appropriate handling/shipping fee may be charged by the *Recipient*.

4.3 The *Recipient* agrees not to apply for any intellectual property protection of the *Original Material*.

### 5. Warranty and Liability

5.1 Any *Material* provided pursuant to this MTA is understood to be experimental in nature. It may have hazardous properties. The *Provider* makes no representations and extends no warranties of any kind, express or implied, as to the fitness of the *Material* for a particular purpose, or that the use of the *Material* will not infringe any patent, copyright, trademark, or other proprietary rights of a third party.

5.2 The *Recipient* assumes all and any liability for damages which may arise from its use, storage or disposal of the *Material*. The *Recipient* shall hold harmless the *Provider* and its researcher/s for any loss, claim or demand which could be raised by the *Recipient*, or made against the *Recipient* by any other party, due to, or arising from, the use of the *Material* by the *Recipient*, except to the extent caused by gross negligence or willful misconduct of the *Provider*.

### 6. Miscellaneous

6.1 The *Original Material* is provided cost-free; however, a handling fee may be charged for its preparation and shipment to the *Recipient*. As applicable, both items are specified in an accompanying letter to this MTA.

6.2 This *MTA* shall be construed according to the laws of the Czech Republic, under exclusion of any of its choice of law and venue principles. Any dispute arising from the interpretation and/or implementation of this *MTA*, which cannot be settled amicably, shall be brought before a competent court of first instance in the Czech Republic.

6.3 This *MTA* shall enter into force on the date of the Disclose of this *MTA* in accordance with paragraph 6.5. It expires after five (5) years or after conclusion of the experiments according to Annex 1, without prior notice by any of the parties. The provisions concerning Publications, Intellectual Property and Liability shall survive this expiration.

6.4 In the event the *Material* or part of it should be under physical control of the *Recipient* before this *MTA* is signed, the terms and provisions shall apply to this *Material* retroactively.

6.5 The Parties acknowledge that Charles University, as a public university and an entity under Art. 2 Par. 1 Letter e) of Act No. 340/2015 Coll., on Contract Register, is subject to the obligation to disclose any contracts it concludes in the contract register (hereinafter "Disclosure" or "Disclose"). The Parties state that this *MTA* is subject to mandatory Disclosure with the exception ANNEX 1. Provider pledges to Disclose the contents of this *MTA* as well as to inform Recipient with no undue delay of the fact that the contents of this *MTA* have been Disclosed.

Information must be sent to the e-mail address of the contact person of the *Recipient*:

Both of parties confirm their acceptance of the terms of this *MTA* by signing below.

Done in duplicate; one original counterpart of this signed *MTA* must be returned to:  
BIOCEV- First Faculty of Medicine, Charles University  
Prumyslova 595, Vestec 25250, Czech Republic

**Signed on behalf of the Provider**

Full Name: Prof. MUDr. ~~Aleksi Šedo, DrSc.~~ *Martin Vokurka* Signed: [REDACTED]

Designation: Dean of the First Faculty of Medicine

Date: 26-01-2021

**Signed on behalf of the Provider Scientist**

Full Name: [REDACTED]

Signed: [REDACTED]

Designation: Principal Investigator

Date: 12.1.2021

**Signed on behalf of the Recipient**

Full Name: Prof. Irit Sagi

Signed: [REDACTED]

Designation: VP for Technology Transfer

Date: June 28, 2020

**Signed on behalf of the Recipient Scientist**

Full Name: [REDACTED]

Signed: [REDACTED]

Designation: Senior Scientist

Date: 12/1/2021


Website:  
biocev.lf1.cuni.cz

E-mail:  
biocev@lf1.cuni.cz

SCHVÁLIL	JMÉNO	DATUM	PODPIS
VĚCNĚ	[REDACTED]	[REDACTED]	[REDACTED]
PŘÁVNĚ	[REDACTED]	[REDACTED]	[REDACTED]



## ANNEX 1



---

**Website:**  
[biocev.lf1.cuni.cz](http://biocev.lf1.cuni.cz)

**E-mail:**  
[biocev@lf1.cuni.cz](mailto:biocev@lf1.cuni.cz)

**Phone:** 